Intended to diagnose a wide range of diseases without drawing blood, the company's Tesseract iC platform includes a novel chemical sensor and combined, multiple dimensions of imaging technology and AI to image the retina, which is the only part of the human body where it is possible to directly see arteries, veins, capillaries, and nerves. The funds, says the company, will be used to conduct research to advance the platform, accelerate the company’s push to obtain US and international regulatory clearances, and ramp up manufacturing, as well as to further enhance the company's unique AI capabilities and prepare the company for commercial launch.
"Our mission is to democratize healthcare on a global scale," says company founder, Dr. Jonathan Rothberg. "Tesseract aims to disrupt healthcare by leveraging the wealth of information that exists in the human eye to promote health equity. Everyone, anywhere, must have access to life saving diagnostic information. With Tesseract’s device, we believe they will."
The company's platform is a binocular eye imaging device that is portable, affordable, and operable by anyone, supporting a post-COVID world focused on cloud-connected telemedicine. The company says it plans to usher in a new branch of diagnostics fusing the best of imaging and laboratory medicine - a truly world's first to support screening, diagnosis, monitoring and treatment in a number of clinical domains to go well beyond ophthalmology to primary care, cardiology, neurology and more.
Investors in the funding round included Foresite Capital, Glenview Capital, and Opaleye.
Jim Tananbaum, CEO and Managing Director of Foresite Capital says, "We are excited about the potential of the Tesseract iC to combine a portable, non-invasive view of the eye with advances in AI. We believe this combination will unlock the potential of the human eye to transform diagnostics."